- Paricalcitol
-
- $0.00 / 1Kg
-
2024-04-03
- CAS:131918-61-1
- Min. Order: 1Kg
- Purity: 99.9%
- Supply Ability: 20tons
- Paricalcitol
-
- $1.00 / 1g
-
2024-01-30
- CAS:131918-61-1
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 10 tons
- Paricalcitol
-
- $0.00 / 1kg
-
2023-03-13
- CAS:131918-61-1
- Min. Order: 1kg
- Purity: 99.0%min. HPLC
- Supply Ability: 1000kg
|
| | Paricalcitol Basic information |
| Product Name: | Paricalcitol | | Synonyms: | 1α,25-Dihydroxy-19-nor-vitaMin D2;Paricalcitol/ 19-nor-1α,25-dihydroxyergocalciferol;PARICALCITOL (10 MG)F0E3030.997MG/MG(AI);PARICALCITOL;19-nor-1alpha,25-dihydroxyvitamin D2;(1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-Hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol;1,3-Cyclohexanediol, 5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethyl-2-hexen-1-yl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, (1R,3R,5Z)-;Paricalcitol, >=98% | | CAS: | 131918-61-1 | | MF: | C27H44O3 | | MW: | 416.65 | | EINECS: | 658-064-6 | | Product Categories: | Vitamin D3 analogs;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;131918-61-1 | | Mol File: | 131918-61-1.mol |  |
| | Paricalcitol Chemical Properties |
| Boiling point | 564.8±50.0 °C(Predicted) | | density | 1.121±0.06 g/cm3(Predicted) | | Fp | 14℃ | | storage temp. | Store at -20°C,unstable in solution, ready to use. | | solubility | DMSO : 100 mg/mL (240.02 mM; Need ultrasonic)Ethanol : 12.5 mg/mL (30.00 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble) | | pka | 14.34±0.40(Predicted) | | InChIKey | BPKAHTKRCLCHEA-UBFJEZKGSA-N | | SMILES | C[C@]12CCC/C(=C\C=C3C[C@@H](O)C[C@H](O)C3)/[C@]1([H])CC[C@]2([H])[C@H](C)/C=C/[C@H](C)C(O)(C)C |&1:1,10,13,16,20,22,26,r| | | CAS DataBase Reference | 131918-61-1(CAS DataBase Reference) |
| | Paricalcitol Usage And Synthesis |
| Description | Paricalcitol was launched as Zemplar in the US for the prevention and
treatment of secondary hyperthyroidism associated with chronic renal failure.
Paricalcitol is a synthetic vitamin D2, namely a novel 1-alpha-hydroxy-19-noranalogue
in which the ring A exocyclic methylene group, typical of all vitamin D
systems, has been replaced by two hydrogen atoms. Paricalcitol is the first
vitamin D analogue marketed for this indication. In patients with chronic renal
failure, Paricalcitol appreciably reduced levels of parathyroid hormone (PTH)
without a significant difference in the incidence rate for hypercalcemia or
hyperphosphatemia when compared with placebo. | | Description | Paricalcitol is a synthetic 1,25-dihydroxy vitamin D2 analog. As vitamin D deficiency, associated with chronic kidney disease, leads to an increase in parathyroid hormone (secondary hyperparathyroidism), paricalcitol is used in renal patients to block parathyroid hormone overproduction. Vitamin D deficiency is also a risk factor in cancer, cardiovascular disease, hypertension, and diabetes, and paricalcitol may have applications in those contexts as well. | | Chemical Properties | White Solid | | Originator | Abbott (US) | | Uses | Antihyperparathyriod | | Uses | 1,25-Dihydroxy vitamin D2 is a potent agonist of the vitamin D receptor. Paricalcitol is a synthetic 1,25-dihydroxy vitamin D2 analog. As vitamin D deficiency, associated with chronic kidney disease, leads to an increase in parathyroid hormone (secondary hyperparathyroidism), paricalcitol is used in renal patients to block parathyroid hormone overproduction. Vitamin D deficiency is also a risk factor in cancer, cardiovascular disease, hypertension, and diabetes, and paricalcitol may have applications in those contexts as well. | | Uses | Synthetic analog of vitamin D. Antihyperparathyroid. | | Definition | ChEBI: Paricalcitol is a seco-cholestane and a hydroxy seco-steroid. It has a role as an antiparathyroid drug. It is functionally related to a vitamin D2. | | Brand name | Zemplar (Abbott). | | Clinical Use | Vitamin D analogue:
Treatment and prevention of secondary
hyperparathyroidism associated with chronic renal
failure | | Metabolism | Extensively metabolised via hepatic and non-hepatic
pathways to form two relatively inactive metabolites.
After oral administration of 3
H-paricalcitol, only about
2% of the dose was eliminated unchanged in the faeces,
and no parent drug found in the urine.
Approximately
70% of the radioactivity was eliminated in the faeces and
18% was recovered in the urine. Most of the systemic
exposure was from the parent drug. |
| | Paricalcitol Preparation Products And Raw materials |
|